Ryutaro Hirose, MD

Organ transplant surgeon

Dr. Ryutaro Hirose performs liver, kidney and pancreas transplants. After graduating from Columbia College of Physicians and Surgeons, he completed clinical research training at UCSF Medical Center as a resident in general surgery and a fellow in molecular medicine and transplantation surgery.

His research interests include the induction of immunologic tolerance, immune monitoring and cancer in transplant patients. He is the recipient of research grants from the National Kidney Foundation, and UCSF School of Medicine. Hirose is a professor of clinical surgery and is board certified by the American Board of Surgery. He is also associate program director for the UCSF General Surgery Residency Program and is involved in teaching surgical residents, fellows and medical students.

Clinics

Connie Frank Transplant Center at UCSF
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Pre-Kidney Fax: (415) 353-8708
Post-Kidney Fax: (415) 353-8381

Hours: 8 a.m. – 5 p.m.

Pancreas Transplant Services
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Pre-Transplant Fax: (415) 353-8708
Post-Transplant Fax: (415) 353-4183

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Board Certification

Surgery, American Board of Surgery

Academic Title

Professor

More about Ryutaro Hirose

Education

Columbia College of Physicians and Surgeons 1989

Residencies

UCSF Medical Center, General Surgery 1997

Fellowships

UCSF Medical Center, Molecular Medicine/Transplantation Surgery

Selected Research and Publications

  1. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Misdiagnosis of Hepatocellular Carcinoma in Patients Receiving no Loco-regional Therapy Prior to Liver Transplant: An Analysis of the OPTN Explant Pathology Form. Clin Transplant. 2017 Sep 07.
  2. Deshpande R, Hirose R, Mulligan D. Liver allocation and distribution: time for a change. Curr Opin Organ Transplant. 2017 Apr; 22(2):162-168.
  3. Hirose R, Heimbach J. Defining disparities in liver transplantation: The devil is in the details. Liver Transpl. 2017 Apr; 23(4):557-558.
  4. Hart A, Schladt DP, Zeglin J, Pyke J, Kim WR, Lake JR, Roberts JP, Hirose R, Mulligan DC, Kasiske BL, Snyder JJ, Israni AK. Predicting Outcomes on the Liver Transplant Waiting List in the United States: Accounting for Large Regional Variation in Organ Availability and Priority Allocation Points. Transplantation. 2016 Oct; 100(10):2153-9.
  5. Gentry SE, Hirose R, Mulligan D. Resolving Misconceptions About Liver Allocation and Redistricting Methodology. JAMA Surg. 2016 Oct 01; 151(10):991-992.
  6. Parekh J, Roll GR, Wisel S, Rushakoff RJ, Hirose R. Effect of moderately intense perioperative glucose control on renal allograft function: a pilot randomized controlled trial in renal transplantation. Clin Transplant. 2016 Oct; 30(10):1242-1249.
  7. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016 Oct; 114(5):587-596.
  8. Edwards EB, Harper AM, Hirose R, Mulligan DC. The impact of broader regional sharing of livers: 2-year results of "Share 35". Liver Transpl. 2016 Apr; 22(4):399-409.
  9. Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy? Gastroenterology. 2016 Feb; 150(2):533-4.
  10. Olmos A, Feiner J, Hirose R, Swain S, Blasi A, Roberts JP, Niemann CU. Impact of a quality improvement project on deceased organ donor management. Prog Transplant. 2015 Dec; 25(4):351-60.
  11. Gentry SE, Segev DL, Kasiske BL, Mulligan DC, Hirose R. Robust Models Support Redistricting Liver Allocation to Reduce Geographic Disparity. Transplantation. 2015 Sep; 99(9):e159-60.
  12. Niemann CU, Feiner J, Swain S, Bunting S, Friedman M, Crutchfield M, Broglio K, Hirose R, Roberts JP, Malinoski D. Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function. N Engl J Med. 2015 Jul 30; 373(5):405-14.
  13. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015 Jun; 61(6):1968-77.
  14. Heimbach JK, Hirose R, Stock PG, Schladt DP, Xiong H, Liu J, Olthoff KM, Harper A, Snyder JJ, Israni AK, Kasiske BL, Kim WR. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology. 2015 May; 61(5):1643-50.
  15. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. Liver Transpl. 2014 May; 20(5):627-8.
  16. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013 Dec; 19(12):1343-53.
  17. Parekh J, Roll GR, Feng S, Niemann CU, Hirose R. Peri-operative hyperglycemia is associated with delayed graft function in deceased donor renal transplantation. Clin Transplant. 2013 Jul-Aug; 27(4):E424-30.
  18. Vagefi PA, Hirose R. Sorafenib combined with locoregional therapy prior to liver transplantation for hepatocellular carcinoma: an update on a previous case report. J Gastrointest Cancer. 2013 Jun; 44(2):246-7.
  19. Mandell MS, Pomfret EA, Steadman R, Hirose R, Reich DJ, Schumann R, Walia A. Director of anesthesiology for liver transplantation: existing practices and recommendations by the United Network for Organ Sharing. Liver Transpl. 2013 Apr; 19(4):425-30.
  20. Vagefi PA, Qian JJ, Carlson DM, Aparici CM, Hirose R, Vincenti F, Wojciechowski D. Native renal function after combined liver-kidney transplant for type 1 hepatorenal syndrome: initial report on the use of postoperative Technetium-99 m-mercaptoacetyltriglycine scans. Transpl Int. 2013 May; 26(5):471-6.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.